NCT00775814 - Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension. | Biotech Hunter

Enrollment

188

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

ObesityHypertension

Interventions

DRUG

Candesartan and Hydrochlorothiazide

Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.

DRUG

Hydrochlorothiazide (HCT)

Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.

Trial Locations (24)

Unknown

Bad Dürrheim

Balingen

Deggingen

Rottweil

Spaichingen

Ingolstadt

München

Passau

Schauenburg

Bocholt

Cologne

Essen

Isselburg

Roetgen

Troisdorf

Wesseling

Rödersheim-Gronau

Dresden

Freital

Machem

Markkleeberg

Wermsdorf

Bad Segeberg

Berlin